DLA Piper Life Sciences Summit
Wednesday, October 4, 2023
DLA Piper’s inaugural Life Sciences Summit took place on Wednesday, October 4 in New York City. The summit brought together pharmaceutical, biotechnology, and medical device companies from around the world and at all stages of the life cycle to discuss emerging trends and challenges facing the industry.
DLA Piper’s life sciences team lead discussions with our clients on diverse topics of interest to high-level lawyers involved in a wide array of issues facing the industry, including:
- Political and legal challenges facing the life sciences industry
- The future of drug pricing in the wake of the Inflation Reduction Act
- Protecting your intellectual property around the world in an ever-changing patent landscape, including the Unified Patent Court and beyond
- The current state of financing and M&A for life sciences companies
- Challenges life sciences companies face when expanding and doing business around the world
- The legal challenges raised by the rapid expansion of artificial intelligence
- FDA regulation of new medical technologies
For more information
Please contact Shannon Tomassi with questions.
Speakers
| Michele Adeleye Vice President and AGC, Chief Counsel Digital Pfizer |
Anne Baker Director of Legal Affairs, Regulatory, Quality & Compliance Dexcom |
|
| Subin Baral Global Deals Leader, Life Sciences Ernst & Young |
Karen Day Senior Counsel Pfizer |
|
| Michael Haughney Director, Global Compliance Monitoring and Analytics Bristol Myers Squibb |
Prof. Dr. Katharina Janus President and CEO ENJOY STRATEGY |
|
| Chris Jewell SVP and General Counsel Taiho Oncology |
Monaya Krause Chief Global Regulatory Counsel GE HealthCare |
|
| Kenneth Peist VP, Intellectual Property Dermavant Sciences |
Angela Riemer SVP, Global Policy & Public Affairs Pfizer |
|
| Philip Ross Global Chairman J.P. Morgan Healthcare Investment Banking |
Aviva Wein Assistant General Counsel, Products Liability Johnson & Johnson |
DLA Piper Speakers
Agenda and CLE materials
9:00 am - Registration and breakfast
10:00 am - Introductory remarks
Loren H. Brown, US Vice Chairman and Chair of US Disputes practice
10:05 am - Political and legal challenges facing the life sciences industry
Former Senator Richard Burr and former Congressman Jim Greenwood
10:55 am - The market for innovation: Current state of life sciences financings and M&A
Andy Gilbert, Philip Ross (J.P. Morgan Healthcare Investment Banking)
11:45 am - Protecting your IP around the world in the era of an ever-changing patent landscape: The UPC and beyond
Gualtiero Dragotti, Nicole Endejann, Chris Jewell (Taiho Oncology), Amy Lydon, Kenneth Peist (Dermavant Sciences)
12:30 pm - Lunch and networking
1:30 pm - The future of drug pricing in the wake of the Inflation Reduction Act
Kirsten Axelsen, Rachel Portman, Angela Riemer (Pfizer)
CLE materials: IRA Drug Act Provisions
2:15 pm - Strategies for companies expanding globally
Jeff Baglio, Subin Baral (Ernst & Young), Prof. Dr. Katharina Janus (ENJOY STRATEGIES), Maruti Narayan, Victoria Rhodes
3:00 pm - Cider and donut break
3:25 pm - The rise of big data: Legal challenges raised by artificial intelligence and other data science trends
Michele Adeleye (Pfizer), Michael Haughney (Bristol Myers Squibb), Danny Tobey, Aviva Wein (Johnson & Johnson)
CLE materials: The Rise of Big Data, The Rise of Big Data - Organizational Governance of Emerging Technologies - AI Adoption in Healthcare
4:10 pm - FDA regulation of new medical technologies
Anne Baker (Dexcom), Karen Day (Pfizer), Perham Gorji, Monaya Krause (GE HealthCare), Geoffrey Levitt, Keo Shaw
CLE materials: FDA Regulatory and Compliance
4:55 pm - Closing remarks
Loren H. Brown, US Vice Chairman and Chair of US Disputes practice
5:00 pm - Cocktail reception
